Advanced Therapies & Regenerative Medicine Congress
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Advanced Therapies & Regenerative Medicine Congress — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
Advanced Therapies & Regenerative Medicine Congress 2027
Date: 9–10 March 2027
Venue: ExCeL London
Location: London, United Kingdom
Event Type: Cell and Gene Therapy Conference & Exhibition
About the Event
The Advanced Therapies & Regenerative Medicine Congress, held annually at ExCeL London, is Europe’s largest commercial cell and gene therapy conference and exhibition. This event convenes over 3,300 global executives, 300+ speakers, and 75+ biotech start-ups across two days. It serves as a platform for leaders of pioneering Advanced Therapeutic Medical Products (ATMPs), including pharma, biotech, and startup companies, to explore cutting-edge technologies, strategies, and collaborations driving the industry forward.
Who Attends
- CEOs, CTOs, and CMOs of ATMP companies
- Research and development executives
- Manufacturing and supply chain leaders
- Regulatory affairs and quality assurance professionals
- Health technology assessment (HTA) bodies and payers
- Clinicians, academics, and researchers
- Biotech start-up founders and investors
Location & Geographic Reach
Event Location: ExCeL London, United Kingdom
Primary Audience: Europe (with global participation from North America, Asia, and beyond)
Audience Reach: Global, featuring multinational pharmaceutical companies, international research institutions, and regulatory bodies.
Sample Buyer Company Profiles
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Orchard Therapeutics | https://www.orchardtherapeutics.com | Chief Executive Officer / Chief Technology Officer | Global leader in gene therapy; active participant in ATMP development and commercialization. |
| 2 | Sofinnova Partners | https://www.sofinnova.com | Partner, Biotechnology Investments | Leading venture capital firm specializing in life sciences and biotech innovation. |
| 3 | Alexion, AstraZeneca Rare Disease | https://www.astrazeneca.com | Head of Neurology and Genomic Medicine Development | Prominent player in rare disease therapies and gene-based treatments. |
| 4 | Complement Therapeutics | https://www.complementtx.com | Chief Executive Officer | Biotech startup focused on gene-editing therapies for rare diseases. |
| 5 | TreeFrog Therapeutics | https://www.treefrog-therapeutics.com | Chief Research & Development Officer | Innovator in cell therapy manufacturing and bioprocessing technologies. |
| 6 | Autolus | https://www.autolus.com | Chief Business Officer | Developer of autologous cell therapies for oncology and autoimmune diseases. |
| 7 | MeiraGTx | https://www.meiragtx.com | SVP, Manufacturing and Supply Chain | Specializes in viral vector gene therapies and regenerative medicine. |
| 8 | National Institutes of Health (NIH) | https://www.nih.gov | Chief, Cell Therapy Manufacturing Section | Public research institution driving advancements in cellular engineering. |
| 9 | Legend Biotech | https://www.legendbiotech.com | Head of Site Strategy and Excellence | Biotech company focused on CAR-T cell therapies and oncology treatments. |
| 10 | Resolution Therapeutics | https://www.resolutiontx.com | SVP, Head of Research and Translational Science | Emerging biotech in gene editing and regenerative medicine. |
| 11 | Beacon Therapeutics | https://www.beacontherapeutics.com | VP, Gene Therapy Research | Specializes in next-generation gene therapy delivery systems. |
| 12 | NHS Centre for Cell, Gene and Tissue Therapeutics | https://www.nhs.uk | Head of Vector Process Development | UK public healthcare provider implementing advanced therapies in clinical practice. |
| 13 | Fondazione Telethon | https://www.telethon.it | Chief Executive Officer | Italian research foundation dedicated to genetic diseases and gene therapy. |
| 14 | University of Oxford | https://www.ox.ac.uk | John Black Professor of Bionanoscience | Academic leader in nanotechnology applications for regenerative medicine. |
| 15 | Forbion Capital Partners | https://www.forbion.com | Operating Partner, Life Sciences | Private equity firm investing in innovative biotech and ATMP ventures. |
Job Profiles, Industries & Event Type
- Key Job Profiles:
- Chief Executive Officer (CEO)
- Chief Technology Officer (CTO)
- Head of Manufacturing / Bioprocessing
- VP, Gene Therapy Research
- Regulatory Affairs Director
- Business Development Manager, ATMPs
- Principal Investigator, Clinical Trials
- Target Industries (per Apollo Classification):
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Healthcare Services
- Investment Banking
- Venture Capital & Private Equity
- Higher Education
- Government Administration
Estimated Attendance
Total Expected Footfall: 3,300+ attendees
Breakdown:
- 300+ speakers and panellists
- 200+ exhibitors and sponsors
- 75+ biotech start-ups
- 2,000+ corporate executives and investors
- 500+ academic and research institutions
Key Focus Areas & Buyer Engagement
This event emphasizes:
- Cell and gene therapy development pipelines
- Manufacturing scalability and GMP compliance
- Regulatory pathways and market access strategies
- Partnerships between academia, industry, and regulators
- Emerging technologies in CRISPR, vector engineering, and allogeneic therapies
Client Product Fit Analysis
To refine buyer targeting, please share your client’s website. Based on the event’s focus:
- If your client offers ATMP manufacturing equipment: Prioritize companies like TreeFrog Therapeutics, MeiraGTx, and NHS Centre for Cell Therapy.
- If your client provides gene-editing platforms: Target Orchard Therapeutics, Beacon Therapeutics, or academic institutions like the University of Oxford.
- If your client specializes in regulatory consulting: Focus on regulatory affairs leaders at Alexion, AstraZeneca, or start-ups seeking market access.
- If your client is an investor: Engage with Forbion Capital Partners, Sofinnova, and biotech start-ups presenting at the event.
Industry Recommendations (per Apollo Classification)
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Healthcare Services
- Investment Banking
- Venture Capital & Private Equity
- Higher Education
- Government Administration
Final Recommendation
This event is highly suitable for B2B engagement, particularly for companies offering:
- ATMP development tools/platforms
- Manufacturing and bioprocessing solutions
- Regulatory and market access services
- Investment and partnership opportunities
Data sheet
Advanced Therapies & Regenerative Medicine Congress – Event Attendee & Buyer Profile Analysis
Event Date: 9–10 March 2027
Location: ExCeL, London, United Kingdom
Event Status: Upcoming
Research Date: 30 June 2026
Event Overview
| Event Name | Advanced Therapies & Regenerative Medicine Congress 2027 |
| Event Date | 9–10 March 2027 |
| Event Status | Upcoming |
| Venue | ExCeL London |
| City | London |
| State / Region | Greater London |
| Country | United Kingdom |
| Organizer | Terrapinn |
| Official Event Website | Advanced Therapies UK 2027 / Terrapinn official event page |
| Event Type | Cell and gene therapy conference & exhibition |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services; IT & Technology |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | 3,000+ attendees (official website); 300+ speakers; 200+ exhibitors; 75+ biotech start-ups |
| Attendance Data Reliability | High for stated 3,000+ attendance figure and exhibitor/speaker/start-up counts; confirmed by official event website |
| Main Purpose of Event | To connect cell and gene therapy leaders, biopharma teams, researchers, investors, regulators, and solution providers around commercialisation, manufacturing, development, regulation, and investment in advanced therapies |
About the Event
The Advanced Therapies & Regenerative Medicine Congress is a major European cell and gene therapy conference and exhibition focused on the commercialisation and scaling of advanced therapy medicinal products (ATMPs). The event brings together senior leaders from pharma, biotech, start-ups, research institutions, clinicians, regulators, HTA bodies, payers, and investors to discuss the science, manufacturing, market access, and partnership models shaping the sector.
From a B2B perspective, this event has strong value for companies selling into life sciences R&D, manufacturing, quality, regulatory, supply chain, lab operations, and clinical translation. It is especially relevant for suppliers of bioprocessing systems, CDMO services, analytics, lab technologies, cold chain, digital compliance tools, and specialized consulting services. The event is well positioned for lead generation because attendees are typically senior, technically informed, and commercially active in high-value procurement and partnership discussions.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Biopharma R&D leaders | Pharmaceutical and biotech companies developing ATMPs | Set technology priorities, evaluate platforms, approve research partnerships | High-value buyers for discovery, translational, and development tools |
| Manufacturing and MSAT teams | Cell therapy, gene therapy, and biologics manufacturers | Influence equipment, process, and scale-up purchasing | Strong fit for bioprocessing, automation, QC, and cleanroom suppliers |
| Regulatory affairs / QA | Biotech, pharma, CDMOs, and platform providers | Guide compliance, validation, documentation, and release decisions | Relevant for QMS, validation, and regulatory software/services |
| Supply chain / operations leaders | ATMP developers, manufacturers, distributors, and logistics partners | Buy cold chain, logistics, inventory, and distribution solutions | Key audience for cold chain, packaging, and logistics providers |
| Clinical and translational teams | Hospitals, academic medical centres, trial networks | Influence trial design, site selection, and therapy adoption pathways | Important for clinical trial tools, patient logistics, and real-world evidence partners |
| Payers / HTA stakeholders | Health technology assessment bodies, insurers, reimbursement stakeholders | Shape access, reimbursement, and evidence requirements | Relevant for market access, HEOR, and patient outcome evidence providers |
| Investors / corporate development | VCs, strategic investors, private equity, corporate venture arms | Fund platform adoption, partnerships, M&A, and licensing | Useful for market intelligence, deal origination, and partnership sourcing |
| Founders / start-up leadership | Biotech start-ups and emerging platform companies | Evaluate vendors, partners, funding, and route-to-market options | High potential for early-stage adoption and services sales |
| Government / policy stakeholders | Regulators, policy bodies, public health organizations | Influence policy, approvals, and ecosystem development | Relevant for policy, public affairs, and regulatory advisory services |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: London | Strong local attendance from London-based life sciences clusters | High | London is a major European biotech, finance, and research hub |
| Host region: Greater London / South East England | Participants from Oxford, Cambridge, Stevenage, Cambridge-London corridor, and South East life sciences clusters | High | Close proximity to major UK R&D ecosystems |
| National reach: United Kingdom | Pharma, biotech, NHS, academia, CDMOs, investors, and service providers across the UK | High | UK ecosystem is central to advanced therapies development |
| European reach | Strong participation from EU biotech clusters, regulators, and research institutions | Very High | The event is positioned as Europe’s largest commercial cell and gene therapy congress |
| International reach | North America, Asia-Pacific, Middle East, and global life sciences stakeholders | High | Official speaker mix includes global commercial, academic, and regulatory participants |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The congress attracts international executives, speakers, exhibitors, and start-ups across Europe and major global life sciences markets |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Orchard Therapeutics | Gene therapy developer | Senior leadership appears on the official agenda; highly relevant ATMP buyer and partner profile | orchard-tx.com | CEO, CBO, R&D Director, Manufacturing Lead | Confirmed Speaker Organization |
| Alexion, AstraZeneca Rare Disease | Biopharma / rare disease | Rare disease and genomic medicine development aligns with advanced therapy strategy and partnerships | astrazeneca.com / alexion.com | VP R&D, Medical Affairs, External Innovation, BD | Confirmed Speaker Organization |
| Legend Biotech | Cell therapy company | Manufacturing and site strategy are core procurement and partnership areas | legendbiotech.com | Head of Site Strategy, MSAT, Procurement, Operations | Confirmed Speaker Organization |
| Beacon Therapeutics | Gene therapy developer | Gene therapy R&D leaders are strong prospects for platform and services suppliers | beacontherapeutics.com | VP Gene Therapy, CMC, Translational Science | Confirmed Speaker Organization |
| MeiraGTx | Gene therapy / biotech | MSAT and manufacturing leaders often evaluate process, analytics, and scale-up solutions | meiragtx.com | SVP MSAT, Manufacturing Director, Quality Head | Confirmed Speaker Organization |
| Autolus | Cell therapy company | Commercial and CMC decision-makers are relevant for outsourcing and manufacturing partnerships | autolus.com | CBO, CMC, Manufacturing, Supply Chain | Confirmed Speaker Organization |
| Resolution Therapeutics | Cell therapy / translational biotech | R&D and translational science leaders are key attendees for platform suppliers | resolution-tx.com | SVP R&D, Translational Science, BD | Confirmed Speaker Organization |
| NHS Blood and Transplant | Public health / cell and gene therapy support | Clinical and therapy infrastructure stakeholder; relevant for logistics, collection, and services | nhsbt.nhs.uk | Director, Clinical Operations, Procurement, Therapy Services | Confirmed Speaker Organization |
| National Institutes of Health | Government research organization | Major public-sector research stakeholder and partner for translational science | nih.gov | Program Director, Research Leader, Grants / Partnership Lead | Confirmed Speaker Organization |
| European Commission | Policy / public sector | Policy and regulatory perspective is important in ATMP commercialisation and access | ec.europa.eu | Policy Officer, Regulatory Affairs, Public Policy | Confirmed Speaker Organization |
| Fondazione Telethon | Research foundation / nonprofit | Translational and funding-oriented partner in rare disease and cell/gene therapy ecosystems | telethon.it | CEO, Research Director, Partnerships | Confirmed Speaker Organization |
| Sofinnova Partners | Life sciences investor | Investment and portfolio development interest across advanced therapies | sofinnova.com | Partner, Principal, Venture Investor | Confirmed Speaker Organization |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Executive Officer / President | Executive | C-level | Sets company strategy, funding priorities, and partnership direction |
| 1 | Chief Scientific Officer / Chief Medical Officer | Scientific / Medical | C-level | Drives platform selection, clinical strategy, and evidence generation |
| 1 | VP / Director of Manufacturing | Manufacturing | Senior | Owns scale-up, capacity, outsourcing, and process technology decisions |
| 1 | Head of MSAT / Process Development | MSAT / Process Development | Senior | Evaluates process tools, analytics, and tech transfer support |
| 1 | Head of Regulatory Affairs | Regulatory | Senior | Key stakeholder for compliance, filings, and global submission strategy |
| 2 | Director of Procurement / Strategic Sourcing Manager | Procurement / Supply Chain | Senior to Mid-senior | Influences supplier selection, contracts, and vendor onboarding |
| 2 | Supply Chain Director / Logistics Lead | Supply Chain | Senior | Relevant for cold chain, distribution, and chain-of-custody solutions |
| 2 | Quality Assurance / Validation Director | Quality | Senior | Buyer for validation, documentation, and quality systems |
| 2 | Business Development Director / Partnerships Director | Business Development | Senior | Evaluates collaborations, licensing, and technology partnerships |
| 3 | Clinical Operations / Program Manager | Clinical Operations | Mid-senior | Coordinates sites, patients, and trial operations for therapy development |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Core commercial audience for ATMP development and commercialization | R&D, CMC, manufacturing, and BD |
| 1 | Biotechnology | Large concentration of attendees and speakers | Platform, workflow, and outsourcing buyers |
| 1 | Medical Devices | Relevant for delivery, collection, and lab systems | Equipment and consumables buyers |
| 1 | Research | Academic and translational leaders are part of the audience mix | Research tools and collaboration services |
| 1 | Hospital & Health Care | Clinical translation, treatment delivery, and patient pathways | Clinical operations and therapy adoption |
| 1 | Venture Capital & Private Equity | Investor participation is common in biotech commercialization events | Deal sourcing and portfolio monitoring |
| 1 | Government Administration | Regulators and public bodies shape access and compliance | Policy, regulation, and public-sector partnership |
| 2 | Medical Practice | Clinicians influence therapy adoption and trial participation | Clinical referral and adoption stakeholders |
| 2 | Logistics & Supply Chain | Cold chain and chain-of-identity are critical in ATMPs | Specialized logistics and packaging |
| 2 | Management Consulting | Strategy and market access advisors often attend | Commercial strategy, operations, and diligence support |
| 2 | Information Technology & Services | Data, systems, and compliance tools support therapy programs | QMS, LIMS, ERP, analytics, and workflow automation |
| 3 | Environmental Services | Cleanroom, sustainability, and lab waste management needs | Facility and compliance services |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 3,000+ attendees | Confirmed | Official event website | Officially stated on event page |
| Exhibitor count | 200+ | Confirmed | Official event website | Officially stated on event page |
| Buyer count | Not publicly confirmed | Confirmed unavailable | Official website does not publish buyer count | Attendance figure not publicly confirmed by the organizer. |
| Speaker count | 300+ | Confirmed | Official event website | Officially stated on event page |
| Sponsor count | Multiple sponsor tiers listed; exact total not publicly summarized | Partially confirmed | Official event website | Sponsor roster visible, but total count not clearly published |
| Historical attendance | 2026 post-event report referenced by organizer; detailed numeric history not reviewed here | Historical / prior-year evidence | Organizer site references 2026 report | Useful for trend validation if report is downloaded |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Cell & gene therapy development | Platforms, reagents, vector systems, translational workflows | Target scientific and CMC decision-makers | R&D tools, reagents, assay services |
| Manufacturing scale-up | Robust, compliant production at higher volumes | Engage MSAT, manufacturing, and operations leaders | Bioprocessing, automation, facilities, CDMO services |
| Regulatory / quality | Compliance, validation, and submission readiness | Meet QA and regulatory leaders looking for efficiency | QMS, validation services, regulatory consulting |
| Supply chain & cold chain | Chain-of-identity, temperature control, delivery reliability | Engage supply chain and logistics decision-makers | Packaging, logistics, tracking, storage |
| Market access / HEOR | Evidence for reimbursement and adoption | Connect with payer and HTA stakeholders | HEOR, outcomes research, access strategy |
| Investment & partnerships | Capital, licensing, co-development, and exit pathways | Engage investors and business development leaders | BD advisory, diligence, corporate development support |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Audience is concentrated in high-value ATMP development, manufacturing, and commercialization roles |
| Decision-maker availability | Very High | Official speaker list includes CEOs, VPs, directors, and policy leaders |
| Data collection potential | High | Sponsor, speaker, and exhibitor content supports segmentation and list building |
| Apollo targeting potential | Very High | Clear industry and title filters exist across pharma, biotech, research, and government |
| Geographic targeting potential | High | Strong UK, European, and global buyer mix can be segmented by geography |
| Best outreach approach | High-touch, technical, account-based | Use role-based messaging tied to manufacturing, compliance, or pipeline-stage pain points |
| Overall lead quality | Very High | Premium event with senior audience and clear commercial intent |
| Best use case | B2B attendee list building and account-based prospecting | Ideal for life sciences vendors, CDMOs, technology providers, and specialized consultants |
| Limitations / risks | Medium | Current-year attendee list is not publicly available from the official source text reviewed here |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals, Biotechnology, Medical Devices, Research, Hospital & Health Care, Government Administration, Venture Capital & Private Equity | Capture the core buyer and influencer universe |
| Departments | Executive, R&D, Manufacturing, Quality, Regulatory, Supply Chain, Procurement, Business Development, Clinical Operations | Target decision-makers and active budget holders |
| Seniority | Manager, Director, VP, CXO, Partner, Head of | Focus on commercial and strategic roles |
| Job titles | CEO, CBO, CSO, CMO, VP R&D, Director of Manufacturing, Head of MSAT, Head of Regulatory Affairs, Procurement Director, Supply Chain Director, BD Director | Prioritize titles most likely to own vendor selection |
| Geography | United Kingdom, Ireland, DACH, France, Benelux, Nordics, Switzerland, United States, Canada | Reflects the event’s European core and international participation |
| Employee size | 11–50, 51–200, 201–500, 501–1000, 1001–5000, 5000+ | Covers start-ups, scale-ups, CDMOs, and large pharma |
| Keywords | cell therapy, gene therapy, ATMP, regenerative medicine, MSAT, bioprocessing, GMP, clinical trials, CDMO, viral vector, quality, regulatory | Improves relevance of event-based prospecting |
| Company type | Public company, privately held biotech, academic medical center, government / public sector, venture-backed start-up | Matches the event’s mixed ecosystem |
Suggested Apollo Search Logic: (Pharmaceuticals OR Biotechnology OR Medical Devices OR Research OR Hospital & Health Care) AND (CEO OR CBO OR CSO OR VP OR Director OR Head of) AND (cell therapy OR gene therapy OR ATMP OR regenerative medicine OR bioprocessing OR GMP OR CDMO OR MSAT OR regulatory OR quality OR clinical trials)
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| Terrapinn – Advanced Therapies UK 2027 official event page | Official organizer page | Event name, dates, venue, city, format, attendee/speaker/exhibitor counts, and agenda speaker organizations | Very High |
| Terrapinn corporate website | Organizer website | Organizer identity and sector positioning | High |
| ExCeL London official website | Venue website | Venue identity and location validation | High |
| Terrapinn agenda / speakers page | Official agenda page | Speaker organizations and seniority evidence used for buyer profiling | Very High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to Advanced Therapies & Regenerative Medicine Congress — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds